David G Hicks1, Swati Kulkarni. 1. Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY 14642, USA. David_Hicks@urmc.rochester.edu
Abstract
CONTEXT: Overexpression of human epidermal growth factor receptor 2 (HER2) is an adverse prognostic parameter for patients with breast cancer. Patients with HER2-positive tumors are, however, likely to gain significant benefit from targeted therapy with trastuzumab. Four large-scale trials have assessed the efficacy and safety of adjuvant trastuzumab. In all 4 trials, disease-free survival and overall survival were significantly improved with adjuvant trastuzumab (36%-52% and 33%-41%, respectively), and improvements were observed in all patient subgroups. OBJECTIVE: To describe, in detail, the clinical benefits of using trastuzumab in the adjuvant setting, and to emphasize the importance this places on the pathologist to correctly identify all patients with HER2-positive tumors with a high degree of accuracy. DATA SOURCES: Published literature on both HER2 testing and the adjuvant use of trastuzumab. CONCLUSIONS: Immunohistochemistry and/or fluorescence in situ hybridization are routinely used to determine HER2 status. Maintaining quality assurance throughout a standardized testing process is essential to achieve accurate and reproducible assay results. Adherence to the new American Society of Clinical Oncology/College of American Pathologists HER2 testing guidelines will help to ensure correct identification of all patients who may benefit from adjuvant trastuzumab and has significant implications for patient outcomes.
CONTEXT: Overexpression of human epidermal growth factor receptor 2 (HER2) is an adverse prognostic parameter for patients with breast cancer. Patients with HER2-positive tumors are, however, likely to gain significant benefit from targeted therapy with trastuzumab. Four large-scale trials have assessed the efficacy and safety of adjuvant trastuzumab. In all 4 trials, disease-free survival and overall survival were significantly improved with adjuvant trastuzumab (36%-52% and 33%-41%, respectively), and improvements were observed in all patient subgroups. OBJECTIVE: To describe, in detail, the clinical benefits of using trastuzumab in the adjuvant setting, and to emphasize the importance this places on the pathologist to correctly identify all patients with HER2-positive tumors with a high degree of accuracy. DATA SOURCES: Published literature on both HER2 testing and the adjuvant use of trastuzumab. CONCLUSIONS: Immunohistochemistry and/or fluorescence in situ hybridization are routinely used to determine HER2 status. Maintaining quality assurance throughout a standardized testing process is essential to achieve accurate and reproducible assay results. Adherence to the new American Society of Clinical Oncology/College of American Pathologists HER2 testing guidelines will help to ensure correct identification of all patients who may benefit from adjuvant trastuzumab and has significant implications for patient outcomes.
Authors: Bradley M Turner; Kristin A Skinner; Ping Tang; Mary C Jackson; Nyrie Soukiazian; Michelle Shayne; Alissa Huston; Marilyn Ling; David G Hicks Journal: Mod Pathol Date: 2015-05-01 Impact factor: 7.842
Authors: Juliann Chmielecki; Jeffrey S Ross; Kai Wang; Garrett M Frampton; Gary A Palmer; Siraj M Ali; Norma Palma; Deborah Morosini; Vincent A Miller; Roman Yelensky; Doron Lipson; Philip J Stephens Journal: Oncologist Date: 2014-12-05
Authors: Jeffrey S Larson; Laurie J Goodman; Yuping Tan; Lisa Defazio-Eli; Agnes C Paquet; Jennifer W Cook; Amber Rivera; Kristi Frankson; Jolly Bose; Lili Chen; Judy Cheung; Yining Shi; Sarah Irwin; Linda D B Kiss; Weidong Huang; Shannon Utter; Thomas Sherwood; Michael Bates; Jodi Weidler; Gordon Parry; John Winslow; Christos J Petropoulos; Jeannette M Whitcomb Journal: Patholog Res Int Date: 2010-06-28
Authors: Gedmante Radziuviene; Allan Rasmusson; Renaldas Augulis; Daiva Lesciute-Krilaviciene; Aida Laurinaviciene; Eduard Clim; Arvydas Laurinavicius Journal: Biomed Res Int Date: 2017-05-28 Impact factor: 3.411